STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump

This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.

NCT Number	NCT07644247
Lead Sponsor	China National Center for Cardiovascular Diseases Collaborators: Beijing Anzhen Hospital, Wuhan Asia Heart Hospital, Shanghai Zhongshan Hospital, Jiangsu Provincial People's Hospital, Second Hospital of Jilin University, Nanjing First Hospital, Nanjing Medical University, Zhejiang Provincial People's Hospital, Sir Run Run Shaw Hospital, Sichuan Provincial People's Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Xinjiang Medical University, Fuwai Yunnan Cardiovascular Hospital, Guangdong Provincial People's Hospital, Henan Provincial Chest Hospital, Fujian Provincial Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, Union hospital of Fujian Medical University, Ruijin Hospital, The 7th People's Hospital of Zhengzhou, Chinese Academy of Medical Sciences, Fuwai Hospital, Xijing Hospital
Conditions	LVAD (Left Ventricular Assist Device) Thrombosis, LVAD, LVAD (Left Ventricular Assist Device), LVAD-related GI Bleed, Bleeding, Thrombosis, Stroke, Hemocompatibility-related Adverse Event +4 more
Enrollment	370 participants
Start Date	2026-06-25
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12